CBIO
Crescent Biopharma, Inc.
NASDAQ · USHealthcareBiotechnology
$15.05+2.03%
Price as of Jul 20, 2026
CBIO profitability
Crescent Biopharma, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 100.0%
- EBITDA margin
- -1336.8%
- EBIT margin
- -1372.9%
- Net margin
- -1363.9%
- Free cash flow margin
- -1200.7%
Returns
- Return on equity
- -88.2%
- Return on assets
- -81.4%
- Return on invested capital
- -88.0%
- Asset turnover
- 0.05x
Cash efficiency
- Cash from operations
- -$69.6M
- Cash per share
- $6.86
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.